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Abstract
Background: Lupus pathogenesis is closely associated with interferon gamma (IFN-γ), which plays a central role in
innate and adaptive immunity. The aim of this study was to evaluate the ex vivo production of IFN-γ after stimulation of
peripheral blood mononuclear cells with phytohemagglutinin (PHA) in patients with lupus, according to disease activity.
Methods: This study included 118 patients with lupus who had undergone IFN-γ-releasing assays (IGRAs) to screen for
tuberculosis. Data on IFN-γ production in negative (nil) and positive (mitogen with PHA) controls were collected and
analysed. The difference (mitogen minus nil) was used to calculate ex vivo IFN-γ production. Disease activity was
evaluated using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K). Poor hospitalisation
outcome was defined as in-hospital mortality or intensive care unit admission. Associations among disease activity, poor
hospitalisation outcome, and ex vivo IFN-γ production were assessed.
Results: The level of ex vivo IFN-γ production was significantly lower in patients with active systemic lupus
erythematosus (SLE) (n = 64) than in those with inactive SLE (n = 54) (median 0.92 vs. 11.06 IU/mL, p < 0.001). Ex vivo
IFN-γ production was correlated with the SLEDAI-2 K (r = − 0.587, p < 0.001). Results of multivariate logistic regression
analysis showed that ex vivo IFN-γ production≤ 7.19 IU/mL was an independent predictor for discriminating active and
inactive lupus. In addition, patients with ex vivo IFN-γ production≤ 0.40 IU/mL had more frequent poor hospitalisation
outcomes than those with ex vivo IFN-γ production > 0.40 (40.0% vs. 9.3%, p = 0.001). The proportion of indeterminate
IGRA results was higher in patients with active lupus than in those with inactive lupus (45.3% vs. 0.0%, p < 0.001)
because of decreased ex vivo IFN-γ production.
Conclusions: Ex vivo IFN-γ production is a useful biomarker for assessing disease activity and predicting poor clinical
outcomes of SLE.
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Background
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease that results from a disruption in im-
mune tolerance to self-antigens, leading to inflammation
of multiple organs [1]. T cells play a major role in SLE
pathogenesis, amplifying inflammation by the secretion
of pro-inflammatory cytokines, helping B cells to gener-
ate autoantibodies, and maintaining the disease through
the accumulation of autoreactive memory T cells [2].
Interferon gamma (IFN-γ) is predominantly produced by
T cells and natural killer cells [3], and it plays a critical
role in lupus [4]. Previous studies have shown that IFN-γ
mRNA expression is increased in peripheral blood mono-
nuclear cells (PBMC) [5], and that serum levels of IFN-γ
are elevated in patients with SLE [6, 7]. In addition, in vivo
experiments in murine models of SLE have shown that el-
evations in IFN-γ mRNA levels are correlated with disease
progression [8, 9].
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Although there is no clinical laboratory test available to
examine serum IFN-γ, the IFN-γ-releasing assay (IGRA) is
a diagnostic test used to detect Mycobacterium tubercu-
losis (TB) infection by measuring the IFN-γ production by
T cells stimulated with TB antigens [10]. Since biologics
such as tumour necrosis factor alpha (TNF-α) inhibitors
make patients susceptible to reactivation of TB, screening
of latent tuberculosis is recommended in the field of
rheumatology [11, 12]. IGRA is composed of three tubes
(nil, mitogen, and TB antigen) for measuring IFN-γ. The
nil tube is a negative control used to measure baseline
IFN-γ production, whereas the mitogen tube is a positive
control used to measure IFN-γ production with phyto-
hemagglutinin (PHA). Therefore, IGRA results of negative
and positive control tubes yield IFN-γ produced at
baseline and by the activated T cells, respectively.
IFN-γ production by T cells has not been used to as-
sess disease activity in SLE before; therefore, we evalu-
ated ex vivo IFN-γ production following stimulation
with PHA in patients with lupus by analysing the results
of IGRA.
Methods
Patient selection and study design
We retrospectively analysed the IGRA results of SLE pa-
tients who had undergone IGRA at Severance Hospital
between November 2009 and December 2016. Patients
with a diagnosis of SLE according to the 1997 revised
American College of Rheumatology classification criteria
[13] were included in the study. The exclusion criteria
were as follows: (i) patients with concomitant auto-
immune disease; (ii) patients with active infection on the
date of the IGRA; (iii) patients with end-stage renal
disease; and (iv) patients with absent complement 3
(C3), C4 or anti-double-stranded DNA (dsDNA) results
on the date of the IGRA. Ultimately, 118 patients were
included in this study. The flowchart for patient selec-
tion is shown in Additional file 1: Figure S1. Among the
patients with active lupus, 13 patients had follow-up
IGRA results available after the lupus became inactive.
For comparison, IGRA results from patients with
rheumatoid arthritis (RA) were retrospectively obtained
for patients who had undergone IGRA before the
administration of biologics such as TNF-α inhibitor.
Data from healthy controls (n = 173) were retrospectively
obtained from individuals who had undergone IGRA for
a regular health check-up at Severance Hospital. This
study was approved by the Institutional Review Board of
Severance Hospital (IRB approval number: 4-2016-1115)
and conducted in accordance with the principles set
forth in the Declaration of Helsinki. The requirement to
obtain informed consent was waived because of the
retrospective nature of the study.
Assessment of clinical and laboratory data
The clinical data collected included age, sex, disease
duration, clinical manifestations, concurrent immuno-
suppressive agents, classification of new onset SLE, and
the SLE Disease Activity Index-2000 (SLEDAI-2 K) [14].
The disease duration was defined as the period from
SLE diagnosis to the date of the initial IGRA, and pa-
tients were defined as having new-onset SLE when IGRA
was performed within 1 month of the initial diagnosis of
SLE. Glucocorticoid dosage was estimated by calculating
the total glucocorticoid dosage that was administered
1 week prior to the IGRA, and was expressed in prednis-
olone equivalent dosage. Clinical manifestations of SLE
included skin rash, photosensitivity, oral ulcers, arthritis,
serositis, nephritis, and neurological, haematological and
immunological disorders, as previously defined [13].
Laboratory data included white blood cell counts; plate-
lets; lymphocyte counts; erythrocyte sedimentation rate
(ESR); levels of haemoglobin, C-reactive protein (CRP),
blood urea nitrogen (BUN), creatinine (Cr), aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
total bilirubin, albumin, C3, C4, and anti-dsDNA; and
urine protein/creatinine ratio (urine P/Cr).
Definition of active SLE according to SLEDAI-2 K scores
During the testing period, the SLEDAI-2 K score of each
patient was evaluated. Laboratory and clinical abnormal-
ities that were not attributable to SLE were excluded
when evaluating SLEDAI-2 K scores. Active SLE was
defined as previously described by Franklyn et al. [15].
Patients with SLEDAI-2 K scores ≥ 5 were defined as
having active SLE, while patients with SLEDAI-2 K
scores < 5 were defined as having inactive SLE. Poor hos-
pitalisation outcome was defined as in-hospital mortality
and/or intensive care unit admission.
Estimation of IFN-γ level assessed by IGRA
For each patient, IGRA was performed in whole blood
samples using the QuantiFERON-TB Gold-In Tube test
(QFT-GIT; Cellestis, QIAGEN, Germany) according to
the manufacturer’s instructions. Briefly, 1 mL of blood
was drawn directly into each of the QuantiFERON®-TB
Gold blood collection tubes. The kit consists of three
blood collection tubes: (i) nil tube (negative control:
whole blood without antigens or mitogen); (ii) mitogen
tube (positive control: whole blood with phytohemagglu-
tinin); and (iii) TB antigen tube (whole blood with pep-
tides of ESAT-6, CFP-10, and TB7.7 proteins simulating
TB-specific antigens). The tubes were incubated over-
night at 37 °C, and the concentrations of IFN-γ (IU/mL)
were measured using an enzyme-linked immunosorbent
assay (ELISA). An automated microplate processor (Evolis
Twin Plus system; Bio-Rad Laboratories, Hercules, CA,
USA) was used to analyse and calculate the results. Ex
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vivo IFN-γ production was estimated by calculating the
difference in IFN-γ production between the mitogen
tube and the nil tube (mitogen minus nil) in order to
measure the ability to produce additional IFN-γ after
PHA stimulation.
Statistical analysis
Data analysis was conducted using either GraphPad Prism
version 5.0 (GraphPad Software, San Diego, CA, USA) or
MedCalc statistical software version 16.2.0 (MedCalc Soft-
ware bvba, Ostend, Belgium). Data were expressed as me-
dians with inter-quartile ranges (IQR) or for categorical
variables, as frequencies and percentages. Continuous vari-
ables were compared using Student’s t test, and categorical
data were compared using the chi-square test or Fisher’s
exact test as appropriate. Comparison of nil and ex vivo
IFN-γ production in patients with paired IGRA results was
performed using the Wilcoxon signed rank test. To com-
pare poor hospitalisation outcome according to ex vivo
IFN-γ production, we used Kaplan-Meier analysis and the
log-rank test. Correlations between age or disease duration
and IFN-γ production in the nil tube, IFN-γ production in
the mitogen tube, or ex vivo IFN-γ production, and the
correlation between ex vivo IFN-γ production and the
SLEDAI-2 K scores were calculated using Pearson’s correl-
ation analysis. Univariate and multivariate logistic regres-
sion analyses were performed with forward stepwise
logistic regression analysis to compare laboratory variables
in differentiating between active and inactive SLE. In multi-
variate analysis, only variables that were statistically signifi-
cant in univariate analysis were included. The cut-off value
of ex vivo IFN-γ production in discriminating active and
inactive SLE and in predicting poor hospitalisation out-
come was evaluated using receiver operator characteristic
(ROC) curve analysis. In all statistical analyses, a two-tailed
p value <0.05 was considered statistically significant.
Results
Baseline characteristics of patients with SLE with active
and inactive disease
Of the 118 patients included in this study, 64 (54.2%) were
classified as having active SLE and 54 (45.7%) as having
inactive SLE. Patients with active SLE had higher SLEDAI-
2 K scores and a larger proportion of them had new-onset
SLE. The median age was older in patients with inactive
SLE, and the disease duration was longer. The white blood
cell count, platelets, lymphocytes, and levels of haemoglo-
bin, albumin, C3, and C4 were lower in patients with active
SLE, whereas the ESR, CRP, BUN, Cr, AST, ALT, anti-
dsDNA levels, and urine P/Cr ratio were higher (Table 1).
The proportion of patients receiving treatment with
glucocorticoids, hydroxychloroquine, and azathioprine was
larger among patients with inactive SLE, whereas the pro-
portion of patients receiving no immunosuppressive agents
was larger among those with active SLE at the time of
IGRA testing (Additional file 2: Table S1).
Comparison of IGRA results in patients with active and
inactive SLE
We compared the IGRA results between patients with
active and inactive SLE. Interpretation of the results of
the IGRA was performed (reported as positive, nega-
tive, or indeterminate) and the IFN-γ level was mea-
sured in each of the three respective tubes. Although
the positivity of the IGRA results was not different
between the groups, the proportion of indeterminate
results was higher in patients with active SLE than in
those with inactive SLE (45.3% vs. 0.0%, p < 0.001)
(Table 2). Patients with active SLE exhibited higher
IFN-γ production in the negative control tube (nil)
and the TB antigen tube (median 0.45 vs. 0.09 IU/mL,
p < 0.001; 0.43 vs. 0.12 IU/mL, p = 0.028). However,
IFN-γ production in the positive control tube (mito-
gen) and ex vivo IFN-γ production (mitogen minus
nil) was decreased in patients with active SLE (median
2.93 vs. 11.15 IU/mL, p < 0.001; 0.92 vs. 11.06 IU/mL,
p < 0.001) (Table 2). All indeterminate results were
due to low ex vivo IFN-γ production. Correlation
analysis between age or disease duration and IFN-γ
production in the nil tube, IFN-γ production in the
mitogen tube, or ex vivo IFN-γ production only re-
vealed negative correlation between age and IFN-γ
production in the nil tube (Additional file 3: Table S2).
In addition, comparison of immunosuppressive agent
usage and indeterminate IGRA results showed that the
proportion of patients with indeterminate IGRA re-
sults was larger in those who were not receiving any
immunosuppressive agents compared to those under-
going concurrent immunosuppressive therapy (19/42
(45.2%) vs. 10/76 (13.1%), p < 0.001).
Comparison of ex vivo IFN-γ production in patients with
SLE, patients with RA, and healthy controls
To evaluate whether decreased ex vivo IFN-γ production
is a characteristic finding in SLE, we compared ex vivo
IFN-γ production between patients with SLE, patients
with RA, and healthy controls. As IGRA testing is rou-
tinely recommended before the initiation of biologics,
we compared the ex vivo IFN-γ production in patients
with SLE with that in patients with active RA who had
undergone IGRA testing before initiating biologics. Pa-
tients with active SLE had the lowest ex vivo IFN-γ pro-
duction, followed by those with inactive SLE, those with
RA, and then healthy controls. Even though differences
in ex vivo IFN-γ production were not observed between
patients with inactive SLE and those with RA, patients
with RA had lower ex vivo IFN-γ production than
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healthy controls (RA median 13.78 IU/mL (IQR 9.64–
16.99 IU/mL) vs. healthy controls 14.60 IU/mL (IQR
12.34–18.33 IU/mL); p < 0.01, Fig. 1a). Patients with ac-
tive SLE also had increased IFN-γ production in the nil
tubes, while differences were not noted between the
other groups (Fig. 1b).
Comparison of ex vivo IFN-γ production before and after
immunosuppressive treatment
We evaluated changes in ex vivo IFN-γ production
(mitogen minus nil) and baseline IFN-γ production (nil)
in patients with active SLE following treatment. In 13 pa-
tients, follow-up IGRA data were available after treatment
Table 2 Comparison of IFN-γ releasing assay (IGRA) results in patients with active and inactive SLE
Variables Active SLE (n = 64) Inactive SLE (n = 54) p value
IGRA results, n (%)
Positive 4 (6.2) 9 (16.6) 0.073
Negative 31 (48.4) 45 (83.3) <0.001
Indeterminate 29 (45.3) 0 (0.0) <0.001
IFN-γ level (IU/mL)
Nil (IU/mL) 0.45 (2.00) 0.09 (0.05) <0.001
Tuberculosis antigen (IU/mL) 0.43 (1.61) 0.12 (0.21) 0.028
Mitogen (IU/mL) 2.93 (7.09) 11.15 (5.03) <0.001
Ex vivo IFN-γ production (IU/mL)a 0.92 (4.93) 11.06 (5.27) <0.001
Values are expressed as the median (interquartile range) or number (percentage)
IFN-γ interferon gamma, IGRA IFN-γ-releasing assay
aEx vivo IFN-γ production was estimated by calculating the difference in IFN-γ production between the mitogen tube and the nil tube (mitogen minus nil)
Table 1 Baseline characteristics of patients with active and inactive SLE
Variables Active SLE (n = 64) Inactive SLE (n = 54) p value
Demographic data
Age, years 33.5 (19.0) 41.5 (20.0) 0.029
Female sex, n (%) 57 (89.0) 42 (77.7) 0.098
Disease duration, (months) 1.0 (75.5) 62.5 (177.0) <0.001
SLEDAI-2 K 8.0 (5.0) 2.0 (2.0) <0.001
New-onset SLE, n (%) 33 (51.5) 5 (9.2) <0.001
Laboratory data
WBC count (/μL) 3570.0 (3225.0) 4900.0 (3450.0) 0.006
Haemoglobin (g/dL) 9.9 (2.5) 13.2 (2.4) <0.001
Platelet count (×1000/μL) 158.5 (125.0) 227.0 (111.0) <0.001
Lymphocyte count (/μL) 580.0 (461.0) 1260.0 (770.0) <0.001
ESR (mm/h) 46.5 (55.0) 19.5 (23.0) <0.001
CRP (mg/L) 9.9 (20.3) 0.6 (1.5) <0.001
BUN (mg/dL) 13.7 (9.9) 12.8 (5.3) 0.025
Cr (mg/dL) 0.6 (0.4) 0.6 (0.2) 0.047
Albumin (mg/dL) 2.9 (1.0) 4.1 (0.5) <0.001
AST (IU/L) 30.5 (27.5) 19.5 (7.0) 0.028
ALT (IU/L) 18.5 (15.5) 16.5 (13.0) 0.036
Total bilirubin (mg/dL) 0.4 (0.2) 0.5 (0.3) 0.726
Complement 3, mg/dL 50.4 (41.0) 85.0 (33.6) <0.001
Complement 4, mg/dL 8.5 (9.4) 16.4 (9.3) <0.001
Anti-dsDNA (IU/mL) 163.5 (360.0) 0.0 (43.0) <0.001
Urine P/Cr ratio 0.4 (2.8) 0.0 (0.1) <0.001
Values are expressed as the median (interquartile range) or number (percentage)
AST aspartate aminotransferase; ALT alanine aminotransferase; BUN blood urea nitrogen; Cr creatinine, CRP C-reactive protein, ESR erythrocyte sedimentation rate,
P/Cr protein/creatinine, SLE systemic lupus erythematosus, SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index-2000, WBC white blood cell
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with immunosuppressive agents, with an interval of at
least 6 months. After successful treatment of SLE, ex vivo
IFN-γ production increased in 12 out of 13 (92.3%) pa-
tients (p < 0.001) (Fig. 2a). Similar to the findings shown in
Fig. 1b, IFN-γ production in the nil tubes decreased after
immunosuppressive treatment (p = 0.021) (Fig. 2b). We
further evaluated the association between ex vivo IFN-γ
production and lupus disease activity measured by the
SLEDAI-2 K score. Ex vivo IFN-γ production was nega-
tively correlated with the SLEDAI-2 K score (r = − 0.587,
p < 0.001) (Fig. 2c).
Clinical utility of ex vivo IFN-γ production in the
discrimination of active and inactive SLE
Logistic regression analysis was performed to compare
the utility of the laboratory parameters in the differenti-
ation of active and inactive SLE. In the univariate
analysis, every laboratory variable except Cr and total
bilirubin was shown to be useful in discriminating active
and inactive SLE. In addition, using ROC analysis, a cut-
off value of ex vivo IFN-γ production ≤ 7.19 IU/mL had
an area under the curve of 0.899, with sensitivity of 84.3
and specificity of 87.0 in the discrimination of active and
inactive SLE. However, in the multivariate analysis, only
ex vivo IFN-γ production ≤ 7.19 (odds ratio (OR) 44.059,
95% confidence interval (CI) 7.315–265.340; p < 0.001),
albumin (OR 0.087, 95% CI 0.019–0.395; p = 0.001), AST
(OR 1.196, 95% CI 1.064–1.344; p = 0.002), and ALT (OR
0.894, 95% CI 0.829–0.963; p = 0.003) were revealed to be
useful in discriminating active and inactive SLE (Table 3).
Comparison of poor hospitalisation outcome according to
ex vivo IFN-γ production
Among the patients included in this study, 68 had
undergone IGRA testing during the admission period.
Fourteen patients had poor hospitalisation outcome. Six
Fig. 1 Nil and ex vivo IFN-γ production in patients with SLE or (RA) and healthy controls. Ex vivo IFN-γ production (a) and nil (b) were compared
between patients with active SLE (n = 64), inactive SLE (n = 54), or RA (n = 222), and healthy controls (n = 173). Data are expressed as medians, and the
error bars indicate interquartile ranges. IFNγ, interferon-gamma, RA rheumatoid arthritis, SLE systemic lupus erythematosus, ns not significant
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patients had in-hospital mortality, whereas eight were
admitted to the intensive care unit. Results of the ROC
curve analysis showed that ex vivo IFN-γ production ≤
0.40 IU/mL was the best cut-off for predicting poor hos-
pitalisation outcome. Results of Kaplan-Meier analysis
with the log-rank test showed that patients with ex vivo
IFN-γ production ≤ 0.40 IU/mL had more frequent poor
hospitalisation outcomes than those with ex vivo IFN-γ
production > 0.40 IU/mL (10/25 (40.0%) vs. 4/43 (9.3%);
p = 0.001) (Fig. 3).
Discussion
Although IFN-γ mainly mediates host defence against
microbial invasion, it is known to have a pivotal role in
SLE. The inhibition of IFN-γ has shown benefits in re-
ducing disease activity in murine models of SLE [16, 17]
and a therapeutic monoclonal antibody against IFN-γ is
being developed for the treatment of SLE [18, 19]. In
this study, we evaluated IFN-γ production in patients
with SLE, using IGRA results obtained during the
screening of latent TB prior to immunosuppressive
treatment. Our data demonstrated that ex vivo produc-
tion of IFN-γ is decreased in patients with active disease
compared to patients with inactive disease. The results
of our study are different from those of previous publi-
cations that have reported increased IFN-γ production
or IFN-γ-related gene expression in SLE, because our
study evaluated IFN-γ production after PHA stimulation
in whole blood [6, 7, 20].
However, our data are not contradictory to previous
findings, in that baseline IFN-γ production (nil results)
in patients with active SLE is increased compared to that
in patients with inactive SLE, in patients with RA, and
in healthy controls. While baseline IFN-γ production
Fig. 2 Ex vivo IFN-γ production increases following immunosuppressive treatment in patients with active SLE and correlates with SLEDAI-2 K.
Changes in ex vivo IFN-γ production (a) and Nil (b) after immunosuppressive treatment in 13 patients with follow-up results from the IFN-γ-
releasing assay. c Correlation between ex vivo IFNγ production and SLEDAI-2 K. IFNγ interferon gamma, SLE systematic lupus erythematosus,
SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index-2000
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increased, ex vivo IFN-γ production after stimulation
with PHA decreased in patients with active SLE. In a
previous study by Hagiwara et al., ex vivo experiments
using enzyme-linked immunospot (ELISPOT) assay
demonstrated that IFN-γ-producing T cells were de-
creased in patients with active lupus [21], which is simi-
lar to our finding. Our study used ELISA, which can
measure the total amount of ex vivo IFN-γ production
in whole blood, excluding baseline production. Since
ELISA is known for its high sensitivity and wide dy-
namic range, measuring ex vivo IFN-γ production by
ELISA can be a suitable biomarker for disease activity in
lupus. Decreased ex vivo IFN-γ production could be as-
sociated with T cell exhaustion, which is a non-
functional state that occurs under conditions of antigen
persistence, such as those that arise during various infec-
tions and cancers [22, 23]. Similar to infection and can-
cer, T cell exhaustion has also been described in SLE
[24]. Excessive auto-antigen exposure in active SLE may
lead to T cell exhaustion. Alternatively, T cells may be-
come unresponsive due to a negative feedback mechan-
ism during periods of overwhelming inflammation. PD-
1, an inhibitory T cell marker, is increased in SLE [25].
Likewise, critically ill patients who are admitted to the
intensive care unit have been shown to demonstrate a
Table 3 Comparison of laboratory variables in differentiating active SLE from inactive SLE, using logistic regression analysis
Univariate analysis Multivariate analysis
Odds ratio 95% CI p value Odds ratio 95% CI p value
WBC count (/μL) 0.999 0.999–0.999 0.009
Haemoglobin (g/dL) 0.408 0.298–0.560 <0.001
Platelet count (×1000/μL) 0.992 0.988–0.997 0.001
Lymphocyte count (/μL) 0.997 0.996–0.998 <0.001
ESR (mm/h) 1.032 1.016–1.048 <0.001
CRP (mg/L) 1.081 1.029–1.137 0.002
BUN (mg/dL) 1.049 1.002–1.098 0.037
Cr (mg/dL) 2.964 0.935–9.396 0.064
Albumin (mg/dL) 0.022 0.005–0.084 <0.001 0.070 0.011–0.441 0.004
AST (IU/L) 1.099 1.048–1.153 <0.001 1.205 1.050–1.383 0.007
ALT (IU/L) 1.023 1.000–1.046 0.047 0.886 0.809–0.971 0.009
Total bilirubin (mg/dL) 1.064 0.747–1.518 0.728
Complement 3, mg/dL 0.951 0.934–0.969 <0.001
Complement 4, mg/dL 0.910 0.868–0.955 <0.001
Anti-dsDNA (IU/mL) 1.009 1.005–1.014 <0.001
Urine P/Cr ratio 5.874 1.772–19.470 0.003
Ex vivo IFN-γ production (IU/mL) 0.721 0.646–0.804 <0.001
Ex vivo IFN-γ production ≤ 7.19 IU/mL 36.257 12.789–102.788 <0.001 49.004 5.871–408.991 <0.001
Concurrent immunosuppressive treatment 0.054 0.017–0.170 <0.001 0.056 0.006–0.469 0.007
AST aspartate aminotransferase, ALT alanine aminotransferase, BUN blood urea nitrogen, Cr creatinine, CRP C-reactive protein, ESR erythrocyte sedimentation rate,
IFN-γ interferon gamma, P/Cr protein/creatinine, SLE systemic lupus erythematosus, WBC white blood cell
Fig. 3 Comparison of poor hospitalisation outcomes according to ex
vivo IFN-γ production. The proportion of patients with poor
hospitalisation outcomes was larger among patients with ex vivo IFN-γ
production ≤ 0.40 IU/mL than in those with ex vivo IFN-γ
production > 0.40 IU/mL. Poor hospitalisation outcome was
defined as in-hospital mortality and/or intensive care unit
admission. IFN-γ interferon gamma
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high proportion of indeterminate results on the IGRA
due to unresponsiveness to mitogen stimulation [26].
Our observations have raised an important issue re-
garding the limitations of the IGRA in SLE. Nearly half
of all patients with active SLE had indeterminate results
from the IGRA, while none of the patients with inactive
SLE had an indeterminate IGRA result. The IGRA re-
sults are dependent on IFN-γ production by TB antigen-
specific T cells. However, when IFN-γ production is
hampered by defective T cells, the sensitivity of the
IGRA may be reduced. Unreliable IGRA results in
patients with T cell defects have been reported in HIV
infection [27]. Our study suggests that the interpretation
of the IGRA requires caution in patients with active SLE.
More importantly, decreased ex vivo IFN-γ production
correlates well with SLEDAI-2 K scores, and the poor
hospitalisation outcome was more frequent in patients
with ex vivo IFN-γ production ≤ 0.40 IU/mL. The find-
ings of our study imply that monitoring ex vivo IFN-γ
production could aid in assessing disease activity and
predicting clinical outcome in SLE. So far, no test is
available to evaluate T cell reactivity for SLE disease ac-
tivity and prognosis, and our data provide the possibility
of developing a diagnostic test to measure ex vivo IFN-γ
production. Furthermore, we demonstrated that de-
creased production of IFN-γ in patients with active SLE
recovers when SLE becomes inactive following immuno-
suppressive treatment. Similar to our findings for SLE,
decreased IFN-γ production in patients with RA has
been shown to recover after TNF-α inhibitor treatment
[28]. Decreased ex vivo IFN-γ production was likewise
noted in our group of patients with active RA as com-
pared with healthy controls. However, decreased ex vivo
IFN-γ production was more pronounced in active SLE
than in active RA in our study.
The strength of our study is that we included a large
number of subjects who had undergone IGRA, an ex
vivo method to estimate IFN-γ production in patients
with SLE. However, the present study has several limita-
tions. First, the clinical and laboratory data and IGRA
results of patients were collected by reviewing the med-
ical records. Since the IGRA is not routinely performed
in patients with SLE, there could have been patient se-
lection bias, resulting in the selection of patients with
more severe SLE in our study. Therefore, our study find-
ings should be validated in future prospective studies.
Second, the effect of immunosuppressive treatment was
not thoroughly controlled. It is possible that immuno-
suppressive treatment affects the decrease in ex vivo
IFN-γ production. However, the proportion of patients
with active SLE treated with glucocorticoids or immuno-
suppressive agents was lower than that of patients with
inactive SLE, as most patients with SLE had undergone
IGRA before initiating potent immunosuppressive
treatment. Therefore, the effect of immunosuppressive
treatment on active lupus may not be significant. Third,
we did not evaluate CD4 T cell numbers. Although we
demonstrated that ex vivo IFN-γ production ≤ 7.19 IU/
mL was an independent predictor for discriminating ac-
tive and inactive lupus regardless of leukopenia and lym-
phopenia, there is a possibility that the level of ex vivo
IFN-γ production is associated with CD4 T cell numbers.
Conclusions
In conclusion, we have demonstrated that ex vivo IFN-γ
production decreases in active SLE, which correlates
with SLEDAI-2 K scores. In addition, the prognosis of
patients with SLE with low ex vivo IFN-γ production
was unfavourable. These findings suggest that ex vivo
IFN-γ production might be a useful biomarker for moni-
toring disease activity in patients with SLE. Furthermore,
special caution in the interpretation of results is required
when IGRA is performed in patients with active lupus
because of a large proportion of indeterminate results.
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